View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
Arthritis Rheumatol 2024 doi: 10.1002/art.42997
IV secukinumab provided rapid and sustained improvements in disease signs and symptoms at Week 16 and through 52 weeks. Kivitz et al. evaluated the long-term efficacy, safety, and tolerability of IV secukinumab in patients with active PsA.
Modern Rheumatology 2024;34:1115–24 doi: 10.1093/mr/roae030
Tanaka et al. observed that in Japanese patients with rheumatoid arthritis treated with tofacitinib, those with absolute lymphocyte counts (ALCs) <0.5x10³ cells/mm³ had a higher risk of serious infections and herpes zoster events compared to patients with higher ALC levels. This threshold may help identify increased infection risk in this population
Rheumatology, 2024. Epub ahead of print doi: 10.1093/rheumatology/keae486
Buch et al. evaluated the efficacy and safety of filgotinib in patients with moderately active rheumatoid arthritis and inadequate response to methotrexate in the FINCH 1 study. At Wk 12, ACR20 response rates were significantly higher with filgotinib 200 mg (77.9%) and 100 mg (67.8%) compared to placebo (43.8%). Safety profiles for both filgotinib doses were similar to adalimumab.
JAMA. 2024;332:881-897 doi: 10.1001/jama.2024.12414
Louis et al. demonstrated risankizumab to significantly improve clinical remission rates compared to placebo in both an induction trial and in a maintenance trial for patients with moderately to severely active ulcerative colitis.
N Engl J Med. 2024;391:1119-1129 doi: 10.1056/NEJMoa23140
Sands et al. demonstrated that 12-week treatment of tulisokibart, a monoclonal antibody targeting TL1A, significantly improved clinical remission rates compared to placebo in patients with moderate-to-severe ulcerative colitis.
Clin Exp Dermatol. 2024 Sep 18;49:1232-1234 doi: 10.1093/ced/llae16
Napolitano et al. conducted a retrospective analysis on patients with moderate-to-severe psoriasiform atopic dermatitis (AD) treated with JAK inhibitors, showing significant improvements in disease severity scores (EASI, P-NRS, DLQI) by Week 4, with 95% of patients achieving EASI-75 and 86% achieving EASI-90 by Week 24.
Inflammopharmacology (2024) 32:3229–46 doi: 10.1007/s10787-024-01563-3
Kandeel et al. compared JAK inhibitors and TNF inhibitors in RA. JAK inhibitors demonstrated better functional improvement via HAQ-DI but showed insignificant difference in CDAI compared to TNF inhibitors; both classes had similar safety.
Clin Exp Dermatol 2024;49:793–800 doi: 1093/ced/llad329
Following discontinuation of secukinumab 150mg or 300mg, a proportion of patients sustained low PASI with clear or almost clear skin despite being drug free for up to 2 years. Patients with a shorter disease duration were less likely to relapse, further supporting the hypothesis that earlier intervention with secukinumab may result in long-term control of moderate-to-severe psoriasis.
Journal Reference: Rheum. 2024 Epub ahead of print doi: 10.1093/rheumatology/keae455.
Adami et al. conducted a retrospective analysis to evaluate the GC sparing effects of JAKi versus bDMARDs in rheumatoid arthritis patients. They found that JAKi therapy was associated with a significant reduction in GC dose compared with bDMARDs. This suggests that JAKi could be more effective in reducing long-term GC exposure in RA patients.
Rheum 2024 doi: 10.1093/rheumatology/keae432 Epub ahead of print
Deodhar et al. investigated the impact on efficacy and safety of escalating secukinumab dose from 150mg to 300mg Q4W in AS patients who did not achieve inactive disease during an initial 16-week period of 150mg secukinumab. At Week 52, clinical safety response rates were similar across groups continuing with 150mg or escalating to 300mg secukinumab.
